Metsera (NASDAQ:MTSR) Shares Gap Up – Here’s What Happened

Shares of Metsera Inc. (NASDAQ:MTSR) gapped up prior to trading on Monday . The stock had previously closed at $29.38, but opened at $31.34. Metsera shares last traded at $28.95, with a volume of 265,955 shares.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on MTSR. Guggenheim increased their price target on Metsera from $56.00 to $62.00 and gave the stock a “buy” rating in a research note on Tuesday, June 10th. Evercore ISI started coverage on Metsera in a report on Tuesday, February 25th. They set an “outperform” rating on the stock. Bank of America assumed coverage on Metsera in a research note on Tuesday, February 25th. They set a “buy” rating and a $38.00 price target for the company. Finally, Cantor Fitzgerald assumed coverage on Metsera in a research note on Tuesday, February 25th. They issued an “overweight” rating on the stock.

Metsera Trading Down 5.5%

The company’s 50-day moving average price is $24.84.

Metsera (NASDAQ:MTSR) last released its earnings results on Monday, May 12th. The company reported ($1.03) EPS for the quarter.

Institutional Investors Weigh In On Metsera

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Strs Ohio bought a new stake in shares of Metsera during the 1st quarter worth $76,000. New York State Common Retirement Fund acquired a new stake in shares of Metsera during the first quarter worth $131,000. Corebridge Financial Inc. purchased a new stake in shares of Metsera during the first quarter valued at $206,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Metsera during the first quarter valued at $248,000. Finally, MetLife Investment Management LLC acquired a new position in shares of Metsera in the 1st quarter valued at $254,000.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.